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Abstract
In Mozambique, the evaluation of retention in HIV care and ART programmes is limited. To assess rate and predictors of
attrition (no retention in care) and HAART effectiveness in HIV-1 infected patients who pay for medication and laboratory
testing in Mozambique, we conducted a multicenter survey of HIV-1-infected patients who started HAART during 2002–
2006. Cox proportional hazard models were used to assess risk of attrition and of therapy failure. Overall, 142 patients from
16 healthcare centers located in the capital city Maputo were followed-up for 22.2 months (12.1–46.7). The retention rate
was 75%, 48% and 37% after one, two and three years, respectively. Risk of attrition was lower in patients with higher
baseline CD4 count (P = 0.022) and attending healthcare center 1 (HCC1) (P = 0.013). The proportion of individuals with CD4
count #200 cells/mL was 55% (78/142) at baseline and decreased to 6% (3/52) at 36 months. Among the patients with
available VL, 86% (64/74) achieved undetectable VL levels. The rate of immunologic failure was 17.2% (95% CI: 12.6–22.9)
per 100 person-years. Risk of failure was associated to higher baseline CD4 count (P = 0.002), likely reflecting low adherence
levels, and decreased with baseline VL $10,000 copies/mL (P = 0.033). These results suggest that HAART can be effective in
HIV-1 infected patients from Mozambique that pay for their medication and laboratory testing. Further studies are required
to identify the causes for low retention rates in patients with low CD4 counts and to better understand the association
between healthcare setting and attrition rate.
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Introduction
Mozambique suffers from one of the highest HIV/AIDS
burdens in the world, with HIV-1 prevalence of 21% in the
southern regions where the capital city Maputo is located [1].
Since mid-1990s antiretroviral therapy (ART) has been available
in Maputo in healthcare settings for patients with medium-high
socioeconomic status, before national ART program was imple-
mented. These patients can afford to pay for their medication,
which are provided by health practitioners, and so they have
access to antiretrovirals different from those being currently given
to the general population. In Kenya and Uganda, treatment
interruption and drug resistance levels are higher among HIV
patients that pay for their own medication and laboratory testing
compared to patients on free-ART programs suggesting that new
strategies may be needed to improve treatment outcomes in this
population [2,3]. At this time, no studies have evaluated the
response to ART among this particular population of patients who
attend the pay-for-care setting in Mozambique. Moreover, the
issue of retention in HIV care programmes has never been
addressed in this special group. The current study was conducted
to evaluate the determinants of attrition (no retention in care) after
the initiation of ART in HIV-1-infected patients undergoing self-
paid medication and laboratory testing in Maputo, Mozambique,
and to assess the effectiveness of ART and the predictors of
immunologic failure in this population.
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Patients and Methods
Ethics Statement
The study was conducted according to the Declaration of
Helsinki with the approval of the ethics committee of the Faculty
of Medicine (Eduardo Mondlane University, Maputo). Written
informed consent was obtained from all participants.
The Maputo HIV-1 Cohort
The Maputo HIV-1 Cohort was established to better describe
the epidemiology of HIV-1 infection and care patterns and
treatment among patients with medium-high socioeconomic status
who self-paid laboratory analyses and ART. The Cohort
prospectively enrolled antiretroviral-naı¨ve HIV-1-infected patients
recruited in 16 healthcare centers throughout the Maputo
province. All patients aged $18 years at ART initiation, with
documented date of start of highly active antiretroviral therapy
(HAART) comprised of at least 3 antiretrovirals, with baseline
CD4 T-cell count (for the six months before HAART initiation)
and with follow-up of $3 months were eligible for this
retrospective survey. The HIV-1 infection was determined on
serum or plasma samples by Uni-Gold Recombigen (Trinity
Biotech, Bray, Ireland) and Determine HIV-1/2 (Abbott, Bedford,
UK) assays. Immune cell counts were determined by flow
cytometry (FACSCalibur, Becton Dickinson, NJ) and plasma
HIV-1 RNA (viral load, VL) by COBAS Amplicor test v1.5
(Roche, Mannheim, Germany), which has a detection limit of 400
copies/mL. Resistance genotyping was performed by ViroSeq
HIV-1 Genotyping System (Abbott, IL).
Statistical Analysis
Baseline characteristics were reported with medians and
interquartile range (IQR) for continuous variables and percentages
for categorical variables. Kolmogorov-Smirnoff test was used to
evaluate the distribution of variables. Fisher exact test or x2 were
used to compare categorical variables. The median of HIV-1
markers and biochemical parameters was calculated for each
patient per semester. A window period of 6 months was allowed
for measurements at each time-point. A median for the study
population was then calculated to evaluate the evolution of each
marker (Wilcoxon tests). Rates of change (slopes) in total
lymphocyte count (TLC), CD4 and CD8 counts were calculated
from 3 consecutive measurements (Deming regression). Differenc-
es in slopes among groups according to different baseline CD4
count were analyzed (Kruskal-Wallis and Mann-Whitney U tests)
and correlation between slopes was assessed (Spearman Rank test).
The risk of attrition (no retention in care) after HAART initiation
and the risk of immunologic failure over time were estimated by
survival analyses using Kaplan-Meier curves and Cox proportional
hazards models. Time was calculated from the date of HAART
initiation to the outcome event. Data were censored on the last
visit date for individuals not retained in care. Information on vital
status (alive or death) for those not retained in care was not
available, thus the definition of outcome measure of attrition from
care combined both patients who died and those lost to follow-up,
who had failed to return for treatment for 3 months after their
scheduled visit for reasons unrelated to death. Immunologic failure
was defined as: fall of CD4 count to baseline (or below) or 50% fall
from on-treatment peak value or persistent CD4 levels below 100
cells/mL [4]. Time to virologic suppression was estimated by
survival analyses for the following endpoints: VL #400 copies/
mL; a reduction of VL .1 log10; a reduction of VL .2 log10.
SPSS (v.17; SPSS Inc., Chicago, IL) and GraphPad Prism (v.4;
San Diego, CA) were used. Statistical significance was defined as
P,0.05 (2-tailed).
Results
Baseline Characteristics
Overall, 142 patients from 16 healthcare centers (HCC) who
started HAART between 2002 and 2006 were eligible. Most
patients (62, 43.7%) were from a centrally located clinic (HCC1);
the remaining patients were from 15 small private clinics located
around Maputo. For convenience of analysis these clinics were
grouped into one and named HCC2. The median follow-up was
22.2 months (12.1–46.7). The median baseline CD4 count was
185 cells/mL (126–290). Baseline VL was available in 54% (76/
142) of patients, who had a median of 5.3 (4.8–5.9) log10 copies/
mL, and was inversely correlated to CD4 counts (r =20.313;
P= 0.006). Median CD4 count and age were similar between
patients with available and unavailable VL. Median CD4 count,
VL and age were similar between patients attending HCC1 and
Table 1. Analyses of risk of attrition from HIV care in the
study population.
Attrition
Analysis, factor N.
N. of cases
(%)
Hazard ratio
(95% CI) P
Univariate
Age at first regimen starta 142 90 (63.4) 0.99 (0.90–1.10) .87
Sex
Men 82 50 (61.0) 1
Women 60 40 (66.7) 1.34 (0.88–2.03) .17
Ethnicity
Other 27 15 (55.6) 1
Black 108 69 (63.9) 1.13 (0.65–1.99) .66
Baseline CD4 countb 142 90 (63.4) 0.82 (0.69–0.96) .016
Baseline log10 HIV-1 RNA
,10,000 8 4 (50.0) 1
$10,000 68 45 (66.2) 1.30 (0.47–3.62) .61
Unknown 66 41 (62.1) 1.05 (0.37–2.93) .93
First-line regimenc
PI-based 16 8 (50.0) 1
NNRTI-based 125 81 (64.8) 1.57 (0.76–3.26) .23
Healthcare center
HCC1 62 34 (54.8) 1
HCC2 80 56 (70.0) 1.80 (1.16–2.79) .009
Multivariable
Baseline CD4 countb 142 90 (63.4) 0.83 (0.70–0.97) .022
Healthcare center
HCC1 62 34 (54.8) 1
HCC2 80 56 (70.0) 1.75 (1.13–2.71) .013
Legend: Adjusted hazard ratios (AHR) were derived from a standard Cox
proportional hazard model. CI, confidence intervals; NNRTI, nonnucleoside
reverse-transcriptase inhibitor; PI, protease inhibitor; HCC, healthcare center.
aPer 5-y increase,
bper 100 cells/mL,
cexcludes one patient who was treated with 1NRTI +1NNRTI +1PI as initial
HAART regimen.
doi:10.1371/journal.pone.0082718.t001
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HCC2. Other baseline characteristics and ART use are listed in
Table S1.
The Risk of Attrition is Associated with Low Baseline CD4
Count and the Healthcare Center
The retention rate was 75%, 48% and 37% after one, two and
three years, respectively (Figure S1). Risk of attrition from HIV
care after initiation of HAART decreased at higher baseline CD4
count (AHR: 0.832; 95% CI: 0.70–0.97; P= 0.022) and was
related to the HCC of origin such that patients attending HCC2
had a significant higher risk of attrition than those attending
HCC1 (AHR: 1.75; 95% CI: 1.13–2.71; P = 0.013) (Table 1).
The Risk of Immunologic Failure is Associated with
Baseline CD4 Count and Viral Load
Median CD4 count increased with time on HAART with a
rapid average increase [113 cells/mL (38–187)] during the first
semester (P,0.001) (Table S2, Figure 1A). Consistently, whereas
the proportion of individuals with CD4 count #200 cells/mL was
55% (78/142) at baseline, this proportion decreased to 6% (3/52)
at 36 months, while those with CD4 count .500 cells/mL
increased from 5% (7/142) to 46% (24/52) (Figure 1B). Patients
who had no available CD4 count at 36 months presented higher
immunosuppression at baseline than patients with available data
(169 cells/mL [111–248] vs 248 [153–329]; P= 0.005). CD8 count
showed small changes over time, while CD4/CD8 ratio increased
to 0.5 (0.4–0.7) at 36 months (P,0.001) (Figure S2A–B). The rate
of immunologic failure was 17.2% (95% CI: 12.6–22.9) per 100
person-years of follow-up. The type of immunologic failure
Figure 1. Immunological response to HAART during follow-up. Legend: A) Median increase in CD4+ T-cell count during the first 3 years of
follow-up according to baseline CD4 T-cell count in the study population; dots represent median values over the study period by CD4 T-cell count
baseline strata; bars represent interquartile range; B) Percentage of patients reaching clinically relevant thresholds of CD4 T-cell count (.200 cells/mL;
.350 cells/mL; .500 cells/mL) during follow-up; C) Kaplan-Meier plots of the probability of immunologic failure according to baseline CD4 T-cell
count (cells/mL) during follow-up.
doi:10.1371/journal.pone.0082718.g001
Figure 2. Kaplan-Meier plots of the probability of virologic response during follow-up. Legend: A) time spent on HAART to achieve a HIV-
1 RNA (VL) #400, copies/mL; B) time spent on HAART to achieve a decrease of HIV-1 RNA (VL) .1 log10; C) time spent on HAART to achieve a
decrease of HIV-1 RNA (VL) .2 log10.
doi:10.1371/journal.pone.0082718.g002
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according to baseline CD4 count strata in the study population is
showed in Table S4. Median time to failure was shorter in patients
with baseline CD4.500 cells/mL than with #200 cells/mL (8.2
months vs 67.5; P,0.001) (Figure 1C). The results of univariate
proportional hazards regression analyses to identify factors
associated with risk of failure are shown in table S3. The only
statistically significant factors were baseline CD4 counts and VL.
All other factors examined, including demographic characteristics
and composition of initial regimen by drug class were not
significant in the univariate analysis. In the multivariable analysis
three factors were included: sex, baseline CD4 counts and VL.
The risk of failure was higher for patients with higher baseline
CD4 counts (AHR: 1.30; 95% CI: 1.10–1.53; P = 0.002) (Table
S3) and lower for patients with baseline VL $10,000 copies/mL
(AHR: 0.33; 95% CI: 0.12–0.91; P = 0.033).
Among the 60 patients with available data at month 24, median
CD4 slopes were uniform across CD4 strata (gain of 6.9 cells/mL/
month [3.2–10.6]), with the exception of individuals with baseline
.500 cells/mL that lost a median of 7 CD4 cells/mL/month
(Table S5). Median TLC slopes were 4.4 cells/mL/month (21.8;
20.0), while median CD8 slopes were 22.3 cells/mL/month
(210.6; 8.9). A positive correlation was observed between CD4
and TLC slopes (r = 0.669; P,0.001), and CD4 and CD8 slopes
(r = 0.452; P= 0.001) (Figure S3).
Virologic Suppression is Achieved in the Majority of
Patients with Available Viral Load Measurements
Among patients with available VL, 86% (64/74) experienced a
decrease to undetectable VL levels after a median of 6.8 months
(5.3–8.4). A VL reduction of .1 log10 occurred in 88% and of .2
log10 in 69% participants (Figure 2). Resistance testing was
performed in 2 patients who failed to suppress viral replication
revealing mutations conferring low-to-high resistance to NRTIs
(M184V, T215F) and NNRTIs (K101E, G190A) [5]. Among
patients who achieved undetectable VL, 8 experienced a rebound
after a median time on HAART of 16.5 months (11.2–19.2). One
of those had mutations conferring intermediate-to-high resistance
to zidovudine and lamivudine (D69N, K70R, M184V).
Discussion
This is the first study evaluating the predictors of attrition after
initiation of HAART as well as HAART effectiveness in a
population paying for antiretrovirals and laboratory testing in
Mozambique. The retention rate (i.e., patients remaining in care
and on ART) was 75%, 48% and 37% after one, two and three
years, respectively. Similar high rates of attrition have been
previously reported in ART programs in several African countries
[6,7]. In Central Mozambique, one study reported that the
proportion of patients retained in care after 12 and 24 months of
ART initiation (free ART) was 68% and 59%, respectively [8]. In
Maputo, a recent study reported a similarly high lost to follow-up
rate (40%) in patients eligible for ART undergoing counselling
before treatment [9]. In this study, independent predictors of high
attrition rate were attending HCC2 and having low CD4 counts at
baseline. Patients who start ART at high CD4 counts (#500 cells/
mL) have decreased risk of progression to AIDS and/or death and
increased likelihood of immune recovery [10,11,12,13,14]. Thus,
high morbidity and mortality may account, at least in part, for the
high rate of attrition observed in our patients with lower CD4
counts [7]. Having low CD4 counts was also described as predictor
of attrition in a large HIV cohort study in India [15]. In addition,
the high cost of antiretrovirals and laboratory tests required for
HIV management might have increased patient-driven treatment
interruptions and limited laboratory testing by some of our
patients, especially those attending HCC2 which serves a wider
and more diverse population across Maputo compared to HCC1.
Similar financial constraints to acquire antiretroviral drugs and
laboratory testing have been reported in patients attending the
private sector in Kenya and Uganda [2,3]. Further studies are
required to identify the causes for low retention rates in patients
with low CD4 counts and to better understand the association
between healthcare setting and attrition rate.
A sustained immunologic response was observed, with most
patients experiencing CD4 recovery above 200 cells/mL, a
clinically meaningful threshold for clinical progression and
opportunistic infections (OI) [16,17]. Nevertheless, the recovery
was slow and only 46% of individuals reached CD4$500 cells/
mL, similarly to the outcome reported by other surveys performed
in high-income and resource-constrained countries [18,19]. A
biphasic kinetic of peripheral blood CD4 T-cell recovery was
observed, characterized by a rapid average increase during the
first semester followed by a slower increase thereafter. The
magnitude of initial immunologic improvements attributable to
HAART is consistent with results of previous longitudinal studies
and might be primarily attributed to memory T-cell release from
lymphoid tissues [20,21]. The results are also in line with previous
studies performed in Mozambique on patients treated for free
under the national ART program [22,23].
As previously found in the EuroSIDA survey, patients with
higher baseline CD4 counts were at higher risk of immunological
failure than patients with lower CD4. One reason for this finding
could lie in the lower rates of ART adherence that individuals with
higher baseline CD4 may have had because at lower risk of OI
[24]. This is consistent with the finding that median CD4 at the
time of immunological failure (520 cells/mL) was above the
threshold of increased OI risk. Interestingly, low baseline VL was
also an independent predictor of immunological failure. This
finding might be explained by the inverse correlation between VL
and CD4 at baseline. Thus, patients with low VL levels and/or
high CD4 counts might have inadequate adherence to ART.
Future studies are needed to measure adherence levels in this
population and its relationship to therapy failure.
The main shortcoming of this study was the limited size of the
study population and the difficulty in retaining patients in care
might have led to a survivor effect. Notwithstanding these
limitations and despite the fact that improved strategies are clearly
required to increase in-care retention levels, this study suggests
that HAART can be effective in HIV-1 infected patients from
Mozambique that pay for their medication and laboratory testing.
Further studies are required to identify the causes for low retention
rates in patients with low CD4 counts and to better understand the
association between healthcare setting and attrition rate.
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Figure S1 Kaplan-Meier estimate of time from antiret-
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according to healthcare centers.
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